Cargando…

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study

OBJECTIVE: To evaluate efficacy and safety of the interleukin‐23p19‐subunit inhibitor, guselkumab, in DISCOVER‐1 patients with active psoriatic arthritis (PsA) by prior use of tumor necrosis factor inhibitor (TNFi). METHODS: The phase 3, randomized, placebo‐controlled DISCOVER‐1 study enrolled patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Ritchlin, Christopher T., Deodhar, Atul, Boehncke, Wolf‐Henning, Soriano, Enrique R., Kollmeier, Alexa P., Xu, Xie L., Zazzetti, Federico, Shawi, May, Jiang, Yusang, Sheng, Shihong, Helliwell, Philip S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010489/
https://www.ncbi.nlm.nih.gov/pubmed/36762512
http://dx.doi.org/10.1002/acr2.11523
_version_ 1784906183682818048
author Ritchlin, Christopher T.
Deodhar, Atul
Boehncke, Wolf‐Henning
Soriano, Enrique R.
Kollmeier, Alexa P.
Xu, Xie L.
Zazzetti, Federico
Shawi, May
Jiang, Yusang
Sheng, Shihong
Helliwell, Philip S.
author_facet Ritchlin, Christopher T.
Deodhar, Atul
Boehncke, Wolf‐Henning
Soriano, Enrique R.
Kollmeier, Alexa P.
Xu, Xie L.
Zazzetti, Federico
Shawi, May
Jiang, Yusang
Sheng, Shihong
Helliwell, Philip S.
author_sort Ritchlin, Christopher T.
collection PubMed
description OBJECTIVE: To evaluate efficacy and safety of the interleukin‐23p19‐subunit inhibitor, guselkumab, in DISCOVER‐1 patients with active psoriatic arthritis (PsA) by prior use of tumor necrosis factor inhibitor (TNFi). METHODS: The phase 3, randomized, placebo‐controlled DISCOVER‐1 study enrolled patients with active PsA (swollen joint count ≥3, tender joint count ≥3, and C‐reactive protein level ≥ 0.3 mg/dl) despite standard therapies; approximately one‐third could have received two or fewer prior TNFi. Patients were randomized to 100 mg of guselkumab every 4 weeks (Q4W); 100 mg of guselkumab at week 0, at week 4, and every 8 weeks (Q8W); or placebo with crossover to guselkumab Q4W at week 24. Efficacy end points of ≥20% and ≥50% improvement in individual American College of Rheumatology (ACR) criteria and achieving the minimal disease activity (MDA) components were summarized by prior TNFi status. RESULTS: In DISCOVER‐1, 118 (31%) patients previously received one or two TNFi. As previously reported, rates for acheiving ≥20% improvement in the composite ACR response at week 24 and week 52 were similar in TNFi‐naive and TNFi‐experienced patients randomized to guselkumab Q4W (76% and 68%, respectively) and Q8W (61% and 58%, respectively). Similar trends were observed for response rates of ≥20% and ≥50% improvement in individual ACR criteria and for achieving individual MDA components at week 24; TNFi‐naive patients were more likely to achieve end points related to physical function and pain than TNFi‐experienced patients. Overall, response rates were maintained or increased through week 52 regardless of prior TNFi use. Through week 60 in guselkumab‐treated TNFi‐naive and TNFi‐experienced patients, 62% and 64%, respectively, reported one or more adverse events (AEs); 4% and 6% had serious AEs, respectively. CONCLUSION: Through 1 year, 100 mg of guselkumab Q4W and Q8W provided sustained improvements across multiple domains in both TNFi‐naive and TNFi‐experienced patients with active PsA.
format Online
Article
Text
id pubmed-10010489
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wiley Periodicals, Inc.
record_format MEDLINE/PubMed
spelling pubmed-100104892023-03-14 Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study Ritchlin, Christopher T. Deodhar, Atul Boehncke, Wolf‐Henning Soriano, Enrique R. Kollmeier, Alexa P. Xu, Xie L. Zazzetti, Federico Shawi, May Jiang, Yusang Sheng, Shihong Helliwell, Philip S. ACR Open Rheumatol Original Articles OBJECTIVE: To evaluate efficacy and safety of the interleukin‐23p19‐subunit inhibitor, guselkumab, in DISCOVER‐1 patients with active psoriatic arthritis (PsA) by prior use of tumor necrosis factor inhibitor (TNFi). METHODS: The phase 3, randomized, placebo‐controlled DISCOVER‐1 study enrolled patients with active PsA (swollen joint count ≥3, tender joint count ≥3, and C‐reactive protein level ≥ 0.3 mg/dl) despite standard therapies; approximately one‐third could have received two or fewer prior TNFi. Patients were randomized to 100 mg of guselkumab every 4 weeks (Q4W); 100 mg of guselkumab at week 0, at week 4, and every 8 weeks (Q8W); or placebo with crossover to guselkumab Q4W at week 24. Efficacy end points of ≥20% and ≥50% improvement in individual American College of Rheumatology (ACR) criteria and achieving the minimal disease activity (MDA) components were summarized by prior TNFi status. RESULTS: In DISCOVER‐1, 118 (31%) patients previously received one or two TNFi. As previously reported, rates for acheiving ≥20% improvement in the composite ACR response at week 24 and week 52 were similar in TNFi‐naive and TNFi‐experienced patients randomized to guselkumab Q4W (76% and 68%, respectively) and Q8W (61% and 58%, respectively). Similar trends were observed for response rates of ≥20% and ≥50% improvement in individual ACR criteria and for achieving individual MDA components at week 24; TNFi‐naive patients were more likely to achieve end points related to physical function and pain than TNFi‐experienced patients. Overall, response rates were maintained or increased through week 52 regardless of prior TNFi use. Through week 60 in guselkumab‐treated TNFi‐naive and TNFi‐experienced patients, 62% and 64%, respectively, reported one or more adverse events (AEs); 4% and 6% had serious AEs, respectively. CONCLUSION: Through 1 year, 100 mg of guselkumab Q4W and Q8W provided sustained improvements across multiple domains in both TNFi‐naive and TNFi‐experienced patients with active PsA. Wiley Periodicals, Inc. 2023-02-10 /pmc/articles/PMC10010489/ /pubmed/36762512 http://dx.doi.org/10.1002/acr2.11523 Text en © 2023 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Ritchlin, Christopher T.
Deodhar, Atul
Boehncke, Wolf‐Henning
Soriano, Enrique R.
Kollmeier, Alexa P.
Xu, Xie L.
Zazzetti, Federico
Shawi, May
Jiang, Yusang
Sheng, Shihong
Helliwell, Philip S.
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study
title Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study
title_full Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study
title_fullStr Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study
title_full_unstemmed Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study
title_short Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study
title_sort multidomain efficacy and safety of guselkumab through 1 year in patients with active psoriatic arthritis with and without prior tumor necrosis factor inhibitor experience: analysis of the phase 3, randomized, placebo‐controlled discover‐1 study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010489/
https://www.ncbi.nlm.nih.gov/pubmed/36762512
http://dx.doi.org/10.1002/acr2.11523
work_keys_str_mv AT ritchlinchristophert multidomainefficacyandsafetyofguselkumabthrough1yearinpatientswithactivepsoriaticarthritiswithandwithoutpriortumornecrosisfactorinhibitorexperienceanalysisofthephase3randomizedplacebocontrolleddiscover1study
AT deodharatul multidomainefficacyandsafetyofguselkumabthrough1yearinpatientswithactivepsoriaticarthritiswithandwithoutpriortumornecrosisfactorinhibitorexperienceanalysisofthephase3randomizedplacebocontrolleddiscover1study
AT boehnckewolfhenning multidomainefficacyandsafetyofguselkumabthrough1yearinpatientswithactivepsoriaticarthritiswithandwithoutpriortumornecrosisfactorinhibitorexperienceanalysisofthephase3randomizedplacebocontrolleddiscover1study
AT sorianoenriquer multidomainefficacyandsafetyofguselkumabthrough1yearinpatientswithactivepsoriaticarthritiswithandwithoutpriortumornecrosisfactorinhibitorexperienceanalysisofthephase3randomizedplacebocontrolleddiscover1study
AT kollmeieralexap multidomainefficacyandsafetyofguselkumabthrough1yearinpatientswithactivepsoriaticarthritiswithandwithoutpriortumornecrosisfactorinhibitorexperienceanalysisofthephase3randomizedplacebocontrolleddiscover1study
AT xuxiel multidomainefficacyandsafetyofguselkumabthrough1yearinpatientswithactivepsoriaticarthritiswithandwithoutpriortumornecrosisfactorinhibitorexperienceanalysisofthephase3randomizedplacebocontrolleddiscover1study
AT zazzettifederico multidomainefficacyandsafetyofguselkumabthrough1yearinpatientswithactivepsoriaticarthritiswithandwithoutpriortumornecrosisfactorinhibitorexperienceanalysisofthephase3randomizedplacebocontrolleddiscover1study
AT shawimay multidomainefficacyandsafetyofguselkumabthrough1yearinpatientswithactivepsoriaticarthritiswithandwithoutpriortumornecrosisfactorinhibitorexperienceanalysisofthephase3randomizedplacebocontrolleddiscover1study
AT jiangyusang multidomainefficacyandsafetyofguselkumabthrough1yearinpatientswithactivepsoriaticarthritiswithandwithoutpriortumornecrosisfactorinhibitorexperienceanalysisofthephase3randomizedplacebocontrolleddiscover1study
AT shengshihong multidomainefficacyandsafetyofguselkumabthrough1yearinpatientswithactivepsoriaticarthritiswithandwithoutpriortumornecrosisfactorinhibitorexperienceanalysisofthephase3randomizedplacebocontrolleddiscover1study
AT helliwellphilips multidomainefficacyandsafetyofguselkumabthrough1yearinpatientswithactivepsoriaticarthritiswithandwithoutpriortumornecrosisfactorinhibitorexperienceanalysisofthephase3randomizedplacebocontrolleddiscover1study